DelveInsight’s Cocaine Use Disorder market report thoroughly explains the Cocaine Use Disorder, historical and forecasted epidemiology, as well as the Cocaine Use Disorder market trends in the 7MM. The report also proffers an analysis of the current Cocaine Use Disorder treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Some of the Important Findings from the Cocaine Use Disorder Market Report
-
According to research issued for the US Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA), roughly 2.0% of the population used cocaine and 0.3% used crack in 2018.
-
According to the United Nations Office on Drugs and Crime (UNODC) study (2019), in 2018, more than two-thirds (79%) of persons receiving treatment for CUDs in the European Union reported using cocaine in combination with heroin or other opioids.
-
Leading players developing therapies for Cocaine Use Disorder include Embera NeuroTherapeutics, KemPharm, Novartis, Omeros, and others.
-
Key Cocaine Use Disorders therapies in the pipeline include EMB-001, KP879, AFQ056, OMS405, and others.
-
EMB-001 (Embera NeuroTherapeutics) is a proprietary combination medicine made up of two FDA-approved medications: metyrapone, a cortisol production inhibitor, and oxazepam, a benzodiazepine.
-
OMS405, a small-molecule peroxisome proliferator-activated receptor gamma (PPAR) agonist, is being tested by Omeros to treat and prevent addiction to substances of abuse such as opioids, nicotine, and alcohol.
Have queries? Request for the sample @ Cocaine Use Disorder Market Outlook
Cocaine Use Disorder Overview
Cocaine use disorder occurs when a person continues to use cocaine despite the fact that it produces cognitive, behavioural, and physical issues. It may also lead to a person’s dependence. Cocaine powder can be snorted or injected after being dissolved in water. Crack is cocaine in the shape of a rock crystal. It can be heated, and the vapours inhaled.
Cocaine Use Disorder Epidemiology Segmentation
The Cocaine Use Disorder report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
-
Cocaine Use Total Prevalence
-
Cocaine Use Disorder Total Prevalent Cases
-
Cocaine Use Disorder Gender-Specific Prevalence
-
Cocaine Use Disorder Age-Specific Prevalence
-
Cocaine Use Disorder Diagnosed and Treatable Cases
Cocaine Use Disorder Treatment Landscape
Despite years of investigation, no pharmacotherapies for Cocaine Use Disorder treatment have been authorised. Despite this, the quest continues, owing to the fact that Cocaine Use Disorder is a terrible illness, and psychosocial treatments, while useful for some individuals, have been proved to be unsuccessful for many others. Recent breakthroughs in our understanding of CUD’s neurology have sparked research into several promising pharmacotherapeutic techniques, and some drugs have shown promise in controlled clinical trials.
Dopamine agonists, such as long-acting amphetamine and modafinil, and GABA agonists/glutamate antagonists, such as topiramate, are two of the most promising pharmaceutical classes so far. Additionally, some pharmaceutical combos (for example, amphetamine and topiramate) may be beneficial.
Cocaine Use Disorder Market Outlook
The Cocaine Use Disorder market will be boosted by an increase in the prevalence of cocaine use and the expected launch of developing medicines such as EMB-001, AFQ056, OMS405, KP879, and others in the forecast period (2021-30). The CUD pipeline offers a ray of hope for a better treatment pattern in the coming years.
Cocaine Use Disorder Pipeline Therapies and Key Companies
-
EMB-001: Embera NeuroTherapeutics
-
KP879: KemPharm
-
AFQ056: Novartis
-
OMS405: Omeros
Learn more about the emerging therapies and companies @ Cocaine Use Disorder Treatment Market
Table of Contents
|
1. |
Report Introduction |
|
2. |
Executive Summary of Cocaine Use Disorder |
|
3. |
Cocaine Use Disorder Market Share at a glance |
|
4. |
Cocaine Use Disorder Disease Background and Overview |
|
5. |
Cocaine Use Disorder Patient Journey |
|
6. |
Cocaine Use Disorder Epidemiology and Patient Population |
|
7. |
Country Wise: Epidemiology of Cocaine Use Disorder |
|
8. |
Cocaine Use Disorder Current Treatment and Medical Practices |
|
9. |
Cocaine Use Disorder Emerging Therapies |
|
10. |
Cocaine Use Disorder Market Size |
|
11. |
Cocaine Use Disorder 7MM: Country-Wise Market Analysis |
|
12. |
Cocaine Use Disorder Market Drivers |
|
13. |
Cocaine Use Disorder Market Barriers |
|
14. |
Cocaine Use Disorder Unmet Needs |
|
15. |
SWOT Analysis |
|
16. |
KOL Views |
|
17. |
Cocaine Use Disorder Reimbursement and market access |
|
18. |
Report Methodology |
|
19. |
DelveInsight Capabilities |
|
20. |
Disclaimer |
|
21. |
About DelveInsight |
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
DelveInsight’s “Cocaine Intoxication – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Cocaine Intoxication, historical and forecasted epidemiology, as well as the Cocaine Intoxication market trends in the 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/